Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Wino115on Nov 10, 2021 1:05pm
274 Views
Post# 34110829

What is it?

What is it?Either someone desperately want's a tax loss or smaller position size regardless of market impact, or Pfizers ex-CMO and oncology specialist Dr. Rothenburg has gotten it completely wrong about  the chance of success for Sort1 Platform or the drug under trial.  

Normally I think the market must know something I don't when there's a decisive move. The natural reaction is to backoff with the assumption "someone" knows something.  But since no one really knows much of anything about THTX except the 100 people here and maybe a similar number on other boards, I discount that.  Their stealth presence is a help in this case!  Let's see how tomorrow goes, but this swoon might get PL's haired raised that he's really getting no sympathy and his shareholders are bailing right before significant news!

PL needs to step up to the plate with an offensive minded message here to support his remaining shareholders!
<< Previous
Bullboard Posts
Next >>